Business
Boeing Prepares For FAA Approval For The 737 Max To Fly Again
(David Ryder/Getty Images)
Seatbelt sign is on

The big four US airlines shed another $5 billion in market cap this week

Together with their regional partners, the carriers control 80% of the US market.

Max Knoblauch

Shares of the big four US airlines — Delta Air Lines, American Airlines, United Airlines, and Southwest Airlines — are wrapping up yet another bleak week amid a host of challenging factors for the aviation industry.

From Monday, March 24, through midday Friday, March 28, Delta and United shares have fallen more than 8%, American shares more than 7%, and Southwest’s more than 3%.

The sell-off represents a loss of $4.8 billion in market cap for the carriers, which with their regional partners control 80% of the US market.

March, and 2025 in general, have not been kind to aviation companies. The S&P Composite 1500 Passenger Airlines index had its worst week since the peak of the pandemic in 2022 earlier this month and is down 22% on the year. So far in 2025, the big four have collectively lost more than $24 billion in market cap — roughly the cost of 180 737 Max 10s.

A familiar batch of issues is still causing the turbulence: tariffs, tariff-impacted travel, tariff-impacted consumer spending, and general safety fears.

25% tariffs on steel and aluminum (metals that planes are made of) went into effect March 12. It’s estimated those tariffs could hike the production cost of a narrow-body aircraft by up to $2.5 million.

A slew of other broad tariffs on goods from Canada, Mexico, China, and Europe have also played a major role in the downturn, in addition to a shift away from momentum stocks that has gut-punched the market in recent weeks. Consumer confidence reached a four-year low this month, and air travel between the US and Canada has plunged as much as 76%. Delta, American, JetBlue, and a few smaller airlines have scaled back their capacity for the quarter April through June.

Repeated safety incidents and close calls in the last few months also might have consumers choosing travel options that stay on the ground. Data from Amanda Demanda Law Group shows that online searches for “are planes safe now?” were up 900% in February.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.